In xenograft models with HSC-2 cells, a mouse-human chimeric mAb, chLpMab-23, exerted antitumor activity using human natural killer cells, indicating that chLpMab-23 may be advantageous for antibody therapy against PDPN-expressing oral cancers [35]. This evidence concerns the gene PDPN and lip and oral cavity carcinoma.